SOURCE: CryoPort, Inc.

May 24, 2005 11:23 ET

CryoPort to Be Featured in ValueRich Magazine

BREA, CA -- (MARKET WIRE) -- May 24, 2005 -- CryoPort, Inc. (OTC: CYRX) announced today that the Company has been selected as a featured article in the June issue of ValueRich magazine.

ValueRich (www.valuerichonline.com) examines the entrepreneurial ideas, strategies and issues surrounding small-cap business and celebrates its rich rewards with articles about the luxury lifestyle and unique products. Its 58,000 subscribers include over 8,000 public CEOs, as well as fund managers, money managers, investment bankers, institutional and qualified private investors, securities brokers, investment advisors, security related attorneys and accountants.

CryoPort's CEO Peter Berry commented, "ValueRich has a history of featuring undiscovered small-cap investment opportunities to its readers. As a relative newcomer to the public market, we were looking for the proper channel to introduce our firm to the institutional marketplace, with a focus on investors who would take a serious look at CYRX as a long-term investment opportunity. Being a featured article in ValueRich is certainly a positive step in that direction and a welcomed opportunity." He added, "We have also accepted an invitation to participate in the ValueRich Small Cap Financial Expo to be held in New York City on September 14th and 15th. The conference will allow CryoPort management to meet with the institutional asset managers that receive the ValueRich magazine. I believe that a personal interaction with these professionals will provide an excellent forum to demonstrate the many opportunities that exist in CryoPort's future."

CryoPort's Investor Fact Sheet is available at http://www.firstcapitalinvestors.com/factsheets/cryo.pdf.

About CryoPort, Inc.

CryoPort, www.cryoport.com, develops leading edge, proprietary, technology driven shipping and storage products for use in the rapidly growing biotechnology and pharmaceutical sectors. The products developed by CryoPort are essential components of the infrastructure required for the testing and research components that make up the foundation of the pharmaceutical and biotechnology industries.

"SAFE HARBOR" NOTE:

Certain statements contained herein constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about the Company's industry, management's beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Since such statements involve risks and uncertainties, the actual results and performance of the Company may turn out to be materially different from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, the Company also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made herein; however, readers should carefully review reports or documents the Company files from time to time with the Securities and Exchange Commission.

Contact Information